Recent

% | $
Quotes you view appear here for quick access.

Deckers Outdoor Corp. Message Board

oilman_12345 103 posts  |  Last Activity: Apr 16, 2014 10:32 PM Member since: Jun 17, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    im8400

    by oilman_12345 Apr 16, 2014 11:11 AM
    oilman_12345 oilman_12345 Apr 16, 2014 10:32 PM Flag

    A Recent Disconnect:
    On March 24, 2014 only a few days prior to the announcement of the Idera P2 trial, Celgene (CELG) announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active "psoriatic arthritis." While I do believe that the approval of this "pill" is great news for Celgene, this is not and was not the intended goal that Idera was striving for in its IMO-8400 trial. According to my research, Idera has never intended to go into this already crowded space (but has stated in its webcasts and news releases that they could partner this out).
    Given these recent announcements, I do believe that investors sold on this news, which is an unwarranted response, hence the disconnect. Maybe investors aren't looking deep enough into the real translation of the data to see that we are actually are on the cusp of something very remarkable. The positive Top-Line data seems to be clearly overlooked, misunderstood and misrepresented by the individual investor. In simple terms, the current stock price is not representative of its real value. We are only seeing a piece of the iceberg floating above the water. I could be wrong, but I don't believe that I am and I will be anxiously waiting for more data from the "higher dose" cohorts to be announced later in Q2 of 2014 which could be a pivotal event.

  • Reply to

    im8400

    by oilman_12345 Apr 16, 2014 11:11 AM
    oilman_12345 oilman_12345 Apr 16, 2014 11:53 AM Flag

    This question that I pose is exactly why I believe that Idera Pharmaceuticals has amassed what I would call the elite team of biotech leaders and investment bankers over the past several quarters. What I am referring to is Idera's highly gifted management team, it's board, leadership, and two main investment firms; Pillar Invest Corp. and Baker Brothers Advisors.

  • oilman_12345 by oilman_12345 Apr 16, 2014 11:11 AM Flag

    Idera Pharmaceuticals - A Buying Opportunity Following The Fade by EXPstocktrader

    April 16, 2014

    If you have been following Idera Pharmaceuticals (IDRA), you know that they have been ramping up as one of the most cutting edge companies in the field of discovery and development of its TLR Antagonists, as well as synthetic DNA- and RNA- based drug candidates which I believe could radically change gene therapies in medicine today.

    Abstract #2570 As Presented at AACR in San Diego, CA on April 7, 2014

    In my review, the preclinical data is quite impressive and almost certainly provides a strong rationale for the phased studies being performed by Idera in ABC-DLBCL and Waldenstrom Macroglobulinemia. We are of course in the early stages, but what is most exciting about this poster is the proof of concept in its TLR Antagonists that are being used in its... In vitro Studies in MYD88 L265P - Positive ABC-DLBCL Cell Lines.

  • oilman_12345 by oilman_12345 Apr 14, 2014 1:38 PM Flag

    Hopefully everyone loaded up on the cheap shares!

  • Reply to

    Ibb greennnn

    by mike_khieu Apr 9, 2014 10:02 AM
    oilman_12345 oilman_12345 Apr 9, 2014 10:05 AM Flag

    last day to get in under 4!

  • oilman_12345 by oilman_12345 Apr 8, 2014 10:33 PM Flag

    It is at the same price as 12/13, however, the following positive data points have been released since:

    Julian Baker and Kevin Neu of BB join the board.
    Coverage issued by Cowen and set price target of 7.
    Had 40 million stock offering to have sufficient funds to run business for 2 more years.
    Lou Brenner named Chief Medical Officer from Radius Health
    Mark Goldberg joins board with experience from Synageva and Genzyme
    Idera also intends to initiate clinical development of IMO-8400 in patients with diffuse large B-cell lymphoma (DLBCL) harboring the MYD88 L265P mutation. The Company has recently submitted a protocol for a Phase 1/2 trial in this indication.
    In December 2013, Idera was cleared to open enrollment in its Phase 1/2 trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, a form of non-Hodgkin lymphoma. The trial is designed to evaluate IMO-8400’s safety, tolerability and potential clinical activity in patients who have a history of relapse or failure to respond to one or more prior therapies. The Company anticipates that patient treatment in this trial will begin in the first half of 2014.
    Idera announced today its plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and dermatomyositis in the first half of 2014.
    Idera Pharmaceuticals announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

  • Reply to

    short interest increased 700k

    by oilman_12345 Mar 12, 2013 9:53 AM
    oilman_12345 oilman_12345 Mar 12, 2013 11:03 AM Flag

    The 50day MA will also move through the 200day MA this week, that may trigger some TA buyers.

  • Reply to

    short interest increased 700k

    by oilman_12345 Mar 12, 2013 9:53 AM
    oilman_12345 oilman_12345 Mar 12, 2013 11:01 AM Flag

    Also, I would expect that some shorts are hedging with Calls, perhaps that will drive a further rally into options expiration.

  • oilman_12345 by oilman_12345 Mar 12, 2013 9:53 AM Flag

    Plenty need to cover! Short interest increased to 14.46M on 2/28 from 13.77M on 2/15.

  • oilman_12345 by oilman_12345 Feb 20, 2013 8:22 AM Flag

    Wedbush downgraded Deckers Outdoor (NASDAQ: DECK) from Outperform to Neutral with a $45 price target citing valuation ahead of Q4 results on 2/28.

    Analyst Corinna Freedman views valuation as a less favorable risk/reward scenario heading into the 4Q print. Shares are trading within 1% of their target valuation and they are stepping to the sidelines given uncertainty surrounding guidance.

    The analyst is comfortable with their conservative $2.60 estimate, which is $0.02 below consensus, although finds it "difficult to discern the market’s expectations for 2013 guidance, which we believe is likely to have a more significant impact on the shares and, given mix shifts towards lower priced transitional styles, is more difficult to estimate."

  • oilman_12345 by oilman_12345 Feb 12, 2013 9:56 AM Flag

    I sure hope DECK spent all their 200M buying back shares on the cheap. Almost at Angel buy point of a half million in July!

  • Reply to

    Shorts starting to cover

    by oilman_12345 Feb 11, 2013 4:38 PM
    oilman_12345 oilman_12345 Feb 11, 2013 10:07 PM Flag

    If their new initiatives in slippers, men's line, new stores, new accounting system, huge buyback payoffs than marketing and PR should just fall into line.

    IMO, they have done some smart things during the past challenging year and believe those initiatives will payoff over the next 18 months.

  • Reply to

    Shorts starting to cover

    by oilman_12345 Feb 11, 2013 4:38 PM
    oilman_12345 oilman_12345 Feb 11, 2013 5:09 PM Flag

    Considering DECK has moved 50% off the bottom a few months ago and there are still that many shorts, that is probably good.

    Also, considering their guidance for the 4th quarter was extremely conservative deck should be on good shape for earnings in a week.

  • oilman_12345 by oilman_12345 Feb 11, 2013 4:38 PM Flag

    The number of shorts dropped 1.2M from 14.6 to 13.4 as recorded on 1/31. There are still plenty more that need to cover.

  • Reply to

    SHORT SQUEEZE !!!!!!!!!!!!!

    by jenaferraro Jan 3, 2013 10:21 AM
    oilman_12345 oilman_12345 Jan 3, 2013 11:23 AM Flag

    It will be interesting to see how many shares Deck mgmt has bought back this past quarter. Over time those buybacks will be a very smart investment for all shareholders. 300M is a significant number of shares.

  • Reply to

    Naked shorting caused this in the first place

    by thebegining6 Nov 28, 2012 11:25 AM
    oilman_12345 oilman_12345 Nov 28, 2012 4:39 PM Flag

    Excellent point, Indian! It will be interesting to see how many shares Deckers bought back during there next quarterly report.

  • Reply to

    Naked shorting caused this in the first place

    by thebegining6 Nov 28, 2012 11:25 AM
    oilman_12345 oilman_12345 Nov 28, 2012 12:43 PM Flag

    It was a great opportunity for smart longs to buy deck on the cheap! Hopefully, plenty did and still can!

  • Reply to

    Estimated Q3 earnings

    by richmartin999 Oct 10, 2012 3:45 PM
    oilman_12345 oilman_12345 Oct 11, 2012 5:09 PM Flag

    From an old presentation Axas was hedged on NG at $6.77.

  • With the company buyback and the increase in shorts it is going to get very interesting. The company can buyback on the order of 5 million shares ($200M) and another 2.2M short in the past two weeks.

  • oilman_12345 oilman_12345 Sep 21, 2012 6:28 AM Flag

    In February 2012, the Company approved a new stock repurchase program to repurchase up to $100,000 of the Company's common stock in the open market or in privately negotiated transactions, subject to market conditions, applicable legal requirements, and other factors. The program did not obligate the Company to acquire any particular amount of common stock and the program could be suspended at any time at the Company's discretion. During the three months ended June 30, 2012, the Company repurchased approximately 1,475,000 shares under this program, for approximately $80,000, or an average price of $54.26. During the six months ended June 30, 2012, the Company repurchased approximately 1,749,000 shares under this program, for approximately $100,000, or an average price of $57.19. As of June 30, 2012, the Company had repurchased the full amount authorized under this program. The purchases were funded from available working capital.

DECK
57.5185-1.1315(-1.93%)11:02 AMEDT